185 related articles for article (PubMed ID: 22991922)
1. New ruthenium(II)-letrozole complexes as anticancer therapeutics.
Castonguay A; Doucet C; Juhas M; Maysinger D
J Med Chem; 2012 Oct; 55(20):8799-806. PubMed ID: 22991922
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium-arene complexes of curcumin: X-ray and density functional theory structure, synthesis, and spectroscopic characterization, in vitro antitumor activity, and DNA docking studies of (p-cymene)Ru(curcuminato)chloro.
Caruso F; Rossi M; Benson A; Opazo C; Freedman D; Monti E; Gariboldi MB; Shaulky J; Marchetti F; Pettinari R; Pettinari C
J Med Chem; 2012 Feb; 55(3):1072-81. PubMed ID: 22204522
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors.
Doiron J; Soultan AH; Richard R; Touré MM; Picot N; Richard R; Cuperlović-Culf M; Robichaud GA; Touaibia M
Eur J Med Chem; 2011 Sep; 46(9):4010-24. PubMed ID: 21703734
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
5. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
Pelletier F; Comte V; Massard A; Wenzel M; Toulot S; Richard P; Picquet M; Le Gendre P; Zava O; Edafe F; Casini A; Dyson PJ
J Med Chem; 2010 Oct; 53(19):6923-33. PubMed ID: 20822096
[TBL] [Abstract][Full Text] [Related]
6. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.
Yahiaoui S; Pouget C; Fagnere C; Champavier Y; Habrioux G; Chulia AJ
Bioorg Med Chem Lett; 2004 Oct; 14(20):5215-8. PubMed ID: 15380230
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes.
David S; Perkins RS; Fronczek FR; Kasiri S; Mandal SS; Srivastava RS
J Inorg Biochem; 2012 Jun; 111():33-9. PubMed ID: 22484498
[TBL] [Abstract][Full Text] [Related]
9. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
10. Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity.
Wood PM; Woo LW; Labrosse JR; Trusselle MN; Abbate S; Longhi G; Castiglioni E; Lebon F; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Jul; 51(14):4226-38. PubMed ID: 18590272
[TBL] [Abstract][Full Text] [Related]
11. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
Vosooghi M; Firoozpour L; Rodaki A; Pordeli M; Safavi M; Ardestani SK; Dadgar A; Asadipour A; Moshafi MH; Foroumadi A
Daru; 2014 Dec; 22(1):83. PubMed ID: 25539909
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents.
Rubner G; Bensdorf K; Wellner A; Kircher B; Bergemann S; Ott I; Gust R
J Med Chem; 2010 Oct; 53(19):6889-98. PubMed ID: 20857911
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity.
Gianferrara T; Bergamo A; Bratsos I; Milani B; Spagnul C; Sava G; Alessio E
J Med Chem; 2010 Jun; 53(12):4678-90. PubMed ID: 20491441
[TBL] [Abstract][Full Text] [Related]
17. The in vitro antitumor activity of arene-ruthenium(II) curcuminoid complexes improves when decreasing curcumin polarity.
Caruso F; Pettinari R; Rossi M; Monti E; Gariboldi MB; Marchetti F; Pettinari C; Caruso A; Ramani MV; Subbaraju GV
J Inorg Biochem; 2016 Sep; 162():44-51. PubMed ID: 27293144
[TBL] [Abstract][Full Text] [Related]
18. (Arene)Cl₂Ru(II) complexes with N-coordinated estrogen and androgen isonicotinates: interaction with sex hormone binding globulin and anticancer activity.
Schobert R; Seibt S; Effenberger-Neidnicht K; Underhill C; Biersack B; Hammond GL
Steroids; 2011 Mar; 76(4):393-9. PubMed ID: 21184767
[TBL] [Abstract][Full Text] [Related]
19. Nitroimidazole and glucosamine conjugated heteroscorpionate ligands and related copper(II) complexes. Syntheses, biological activity and XAS studies.
Pellei M; Papini G; Trasatti A; Giorgetti M; Tonelli D; Minicucci M; Marzano C; Gandin V; Aquilanti G; Dolmella A; Santini C
Dalton Trans; 2011 Oct; 40(38):9877-88. PubMed ID: 21709917
[TBL] [Abstract][Full Text] [Related]
20. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
